OneDigital Investment Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 12.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 31,652 shares of the medical instruments supplier's stock after acquiring an additional 3,534 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Becton, Dickinson and Company were worth $7,181,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB boosted its stake in shares of Becton, Dickinson and Company by 13.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock worth $39,951,000 after buying an additional 20,859 shares during the last quarter. Busey Bank raised its position in Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock valued at $15,031,000 after acquiring an additional 2,399 shares in the last quarter. Centre Asset Management LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $8,382,000. Finally, Nordea Investment Management AB grew its stake in shares of Becton, Dickinson and Company by 31.0% during the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock worth $647,082,000 after purchasing an additional 673,568 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on BDX shares. Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Wednesday. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a research report on Monday, April 7th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $272.86.
Get Our Latest Stock Analysis on BDX
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. The trade was a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Richard Byrd sold 459 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now directly owns 6,952 shares of the company's stock, valued at $1,598,960. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,578 shares of company stock valued at $795,986. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Price Performance
Shares of BDX traded up $0.85 during mid-day trading on Friday, hitting $205.30. 1,690,556 shares of the company were exchanged, compared to its average volume of 1,733,176. The stock has a market cap of $58.95 billion, a price-to-earnings ratio of 34.10, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1-year low of $193.03 and a 1-year high of $251.99. The company has a 50 day moving average of $218.51 and a 200-day moving average of $227.33. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.03%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 69.10%.
Becton, Dickinson and Company declared that its board has approved a stock buyback program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
